Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

Brand drugFirst approved 2018

Vizimpro(Dacomitinib)Pfizer Inc. logoPFE

Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Pfizer Inc.

$2.6M

Medicare cost, 2024

Medicare drug plans spent $2.6 million on Vizimpro (dacomitinib) in 2024, for 163 prescriptions and refills filled by 37 patients. At about $15,894 per prescription it is a high-cost drug. New York accounts for the most spending ($595,099, 23% of the total). It is made by Pfizer Inc. (PFE).

Medicare cost, 2024

$2.6M

-6.6% from 2023

Prescriptions

163

$15,894.44 per claim

Patients

37

37 prescribers

Total spending, 2024

$2.6M

$70,021.44 per patient

Questions and answers

How much does Medicare spend on Vizimpro?

Medicare prescription drug plans paid $2.6M for Vizimpro in 2024, for 163 prescriptions and refills to 37 patients (down 6.6% from 2023). The average cost per claim was $15,894.44.

Which state spends the most on Vizimpro?

New York had the highest Medicare cost for Vizimpro in 2024: $595K for 37 claims, followed by California ($401K).

Who prescribes Vizimpro the most?

Bob T Li, medical oncology in New York, NY, had the highest Medicare cost for Vizimpro in 2024: 17 claims costing $268K.

Who makes Vizimpro?

Vizimpro is made by Pfizer Inc. (PFE), listed in the Medicare spending data as Pfizer US Pharm.

Spending over the years

Medicare spending by year

All plans and makers

Prescriber data: cost by year

Medicare spending on Vizimpro was $2.6M in 2024, after a high of $2.8M in 2023.

By state

Where the prescribers practice, 2024

Medicare cost by state

States with the highest cost

Top prescribers of Vizimpro, 2024

By Medicare drug cost

PrescriberTypeClaimsPatientsCost
Bob T Li New York, NYMedical Oncology17Under 11$268K
Jyoti Malhotra New Haven, CTHematology-Oncology13Under 11$204K
Jorge A Diaz Huntsville, ALHematology-Oncology12Under 11$185K
Bety C Ciobanu Chicago, ILInternal Medicine11Under 11$165K
Sumeet Bhatia Indianapolis, INMedical Oncology12Under 11$132K

Prescriber data by year

YearPrescribersClaimsPatientsCost
20223215030$2.4M
20233717435$2.8M
20243716337$2.6M

Makers, 2024

Spending by manufacturer as listed in the spending data

ManufacturerClaimsSpending
Pfizer US PharmPFE logoPFE163$2.6M

Codes

National drug codes (packages)
3
RxNorm concept IDs
2058915, 2058922, 2058924, 2058926, 2058930
Application numbers
NDA211288

More drugs: Medicare drug spending and the Prescriptions view.

Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.

LinkedInLinkedInXXYouTubeYouTube